PPARG and Hyperglycemia: PPARγ agonists, rosiglitazone and pioglitazone enhance insulin sensitivity, lower hyperglycemia and free fatty acid concentrations by improving glucose and lipid metabolism, improves adipokine profile and reduce adipose tissue inflammation [7–9].